It hasn’t been a great year for Alzheimer’s drugs—or really a great decade, even. The most recent Phase 3 trial cancellation was a study…
On Thursday, Biogen, along with its Japanese partner Eisai, announced it would be canceling two late-stage trials testing their drug aducanumab. The drug was…
Jeff Borghoff and his wife Kimberly speak about participating in the Biogen drug trial testing aducanumab, a drug that targets beta-amyloid. The late-stage trial…
Dementia is steadily rising in the ranks of causes of death in America, according to a new report released by the National Center for…
It sounds like something out of a science fiction movie with a Goop-esque twist: a company called Ambrosia offers plasma transfusions of “young” blood into…
Sign up for a weekly digest of the latest research on Alzheimer’s and brain health.
Follow us